Image default
Mental Health

Safety and immunogenicity of COVID-19 peptide vaccine




In a study published in Nature, researchers from University Hospital Tübingen have been investigating the results from a Phase I trial for a new vaccine against SARS-CoV-2 variants.



Source link

Related posts

Bruker announces new results in deep, unbiased plasma proteomics, PaSER 1.1 software and new cross-linking consumables at US HUPO 2021

Globe Health News

Scientists develop world's first test to accurately predict mood disorders

Globe Health News

Researchers discover titanium oxide nanoparticle that recognizes SARS-CoV-2’s non-structural protein 1

Globe Health News

Leave a Comment